



## 11TH ANNUAL CARDIOVASCULAR RESEARCH INSTITUTE (CVRI) SYMPOSIUM April 10, 2024

### **NEEDS STATEMENT**

There is a critical need to address the rapidly evolving landscape of medical research and technology, particularly in the field of cardiovascular health. As medical research and technology change rapidly, it is increasingly important for physicians, PhD faculty, residents, fellows, medical students, graduate school trainees, and other healthcare professionals to stay informed of new evidence. This symposium is designed as a platform to share and discuss state-of-the-art ongoing, innovative, and new cardiovascular research with the ultimate goal of translating research into clinical practice. Despite the abundance of new findings and technologies, there exists a knowledge gap among healthcare professionals regarding the latest developments in cardiovascular research and their application in clinical settings. Newly learned pathways can serve as potential mechanisms and alternative strategies in new research applications, but without awareness and understanding among healthcare professionals, these advancements may not be effectively integrated into patient care. Additionally, topics on how to apply new diagnostic and imaging techniques can create opportunities for collaboration with the developers of these techniques in new research protocols, fostering a multidisciplinary approach to improving cardiovascular care. Therefore, there is a critical need to address the knowledge gap and equip healthcare professionals with the necessary information and skills to leverage the latest advancements in cardiovascular research for the benefit of patient outcomes.

### **TARGET AUDIENCE**

This activity is for Physicians, Fellows, Residents, Trainees, Physician Assistants, and Nurses/Nurse Practitioners specializing in cardiovascular research and care, and all other practitioners interested in cardiovascular sciences.

### **EDUCATIONAL OBJECTIVES**

At the conclusion of this activity, the participant should be able to:

- Identify risk modifications in congenital heart disease.
- Analyze gene editing-based approaches.
- Evaluate the role of fibrinogen in thromboinflammation.
- Interpret the role of vascular endothelium in metabolic homeostasis.

### **EDUCATIONAL METHODS**

Lecture and Question & Answer

### **EVALUATION**

Evaluation by questionnaire will address program content, presentation, and possible bias.

### **ACCREDITATION/CREDIT DESIGNATION**

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 3.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **OBTAINING CREDIT**

Two (2) business days after the course, an email will follow from the Baylor College of Medicine, Division of Continuing Professional Development with instructions for completing the evaluation and obtaining your CME Certificate, CE Certificate, or Certificate of Attendance.

#### **Contact Information**

Baylor College of Medicine

Email: [cpd@bcm.edu](mailto:cpd@bcm.edu)

Division of Continuing Professional Development

Phone: 713.798.8237

One Baylor Plaza, MS: BCM 155

Fax: 713.798.7955

Houston, TX 77030-3411

**Visit our website at [cpd.education.bcm.edu](http://cpd.education.bcm.edu) for information about additional CME activities.**



**DRUG/DEVICE STATUS DISCLOSURE**

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law.

Baylor College of Medicine requires that all faculty/presenters disclose an unlabeled use or investigational use of pharmaceutical and medical device products, and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

**DISCLOSURE OF FINANCIAL RELATIONSHIPS WITH COMMERCIAL INTERESTS**

**DISCLOSURE POLICY**

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CME activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME’s validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.

**DISCLOSURES**

FACULTY	PLANNING COMMITTEE	PRESENTER	DISCLOSURE
<b>Gang Bao, PhD</b> Foyt Family Professor Rice University		•	Nothing to disclose
<b>Biykem Bozkurt, MD, PhD</b> Associate Director of Cardiovascular Research Institute Baylor College of Medicine		•	<u>Type of financial relationship:</u> Consultant, <u>Ineligible companies:</u> Bayer, Astra Zeneca, Sanofi, sc Pharma, Abbott, Vifor, Zoll/ Respicardia, <u>Topic:</u> Heart Failure
<b>Miguel Cruz, PhD</b> Professor and Division Chief Baylor College of Medicine		•	Nothing to disclose



11TH ANNUAL CARDIOVASCULAR RESEARCH INSTITUTE (CVRI) SYMPOSIUM  
April 10, 2024

FACULTY	PLANNING COMMITTEE	PRESENTER	DISCLOSURE
<b>Bhanu Ganesh, PhD</b> Assistant Professor McGovern Medical School		•	Nothing to disclose
<b>Sandra Guerra</b> Sr. Business Operations Associate Cardiovascular Research Institute Baylor College of Medicine	•		Nothing to disclose
<b>Jason Karch, PhD, BA</b> Assistant Professor Baylor College of Medicine		•	Nothing to disclose
<b>Peter Lillehoj, PhD</b> Associate Professor Rice University		•	Nothing to disclose
<b>Richelle Lopez, PhD</b> Senior Coordinator, Business Operations Baylor College of Medicine	•		Nothing to disclose
<b>Andrew Marks, MD</b> Professor and Chair Department of Physiology and Cellular Biophysics Columbia University		•	<u>Type of financial relationship:</u> Board Membership, <u>Ineligible company:</u> ARMGO Pharma, <u>Topic:</u> RyR Therapeutics
<b>Christina Miyake, MD, MS</b> Associate Professor in the Department of Molecular Physiology and Biophysics Baylor College of Medicine		•	Nothing to disclose
<b>Shaine Morris, MD, MPH</b> Associate Professor Baylor College of Medicine		•	<u>Type of financial relationship:</u> Consultant, <u>Ineligible company:</u> Ayti Biopharma, <u>Topic:</u> Vascular EDS Trial.
<b>Xinchun Pi, PhD</b> Associate Professor Cardiovascular Research Institute Baylor College of Medicine		•	Nothing to disclose
<b>Xander Wehrens, MD, PhD – Activity Director</b> Professor Baylor College of Medicine	•		<u>Type of financial relationship:</u> Consultant, <u>Ineligible company:</u> Rocket Pharmaceuticals, <u>Topic:</u> Heart Disease.



## 11TH ANNUAL CARDIOVASCULAR RESEARCH INSTITUTE (CVRI) SYMPOSIUM

April 10, 2024

### **DISCLAIMER**

This activity is designed for healthcare professionals for educational purposes. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.

While Baylor College of Medicine makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Faculty/presenters have submitted materials for this syllabus for printing in advance so that you may have an outline or summary of the main points of their presentation. Often this differs from the final version of their slides as faculty/presenters make revisions up until the day of the meeting.

Additionally, some images (cartoons, drawings and some photographs) shown on the screen may not be present in your educational materials because of publishers' requirements for reprinting of copyrighted images.

### **NOTICES**

Faculty, topics, program schedule, and credit are subject to change.

Audio or videotaping is prohibited without written permission from the Activity Directors and the Division of Continuing Professional Development, Baylor College of Medicine, Houston, Texas.